Yahoo Finance • 4 months ago
Cassava Sciences, Inc. Shareholders of Record Received Warrants to Purchase Shares of Common Stock Warrants Trade on Nasdaq Under the Ticker “SAVAW” Warrant Holders Who Choose to Exercise During an Early Period Will Receive an Additional... Full story
Yahoo Finance • 5 months ago
Ascending Bar Chart Line Invest Financial Newspaper Stock Market Quote Rally Bull Getty In less than a week, Wall Street will turn the page on what's been a stellar year for optimists. The 30-component Dow Jones Industrial Average climbed... Full story
Yahoo Finance • 6 months ago
NEW YORK, Nov. 13, 2023 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Cassava Sciences, Inc. (“Cassava” or the “Company”) (NASDAQ: SAVA). Such investors are advised to contact Robert S. Willoughby... Full story
Yahoo Finance • 6 months ago
Enrollment completed for Phase 3 trials evaluating oral simufilam in Alzheimer's. Over 1,900 patients randomized in on-going Phase 3 trials.Top-line results for 52-week Phase 3 trial expected approximately year-end 2024; top-line results f... Full story
Yahoo Finance • 6 months ago
1,929 patients randomized in a pair of Phase 3 trials to evaluate oral simufilam in Alzheimer's disease dementia.Top-line results for on-going, 52-week Phase 3 trial expected approximately year-end 2024.Top-line results for on-going, 76-we... Full story
Yahoo Finance • 7 months ago
NEW YORK, Oct. 27, 2023 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Cassava Sciences, Inc. (“Cassava” or the “Company”) (NASDAQ: SAVA). Such investors are advised to contact Robert S. Willoughby... Full story
Yahoo Finance • 7 months ago
Safety Finding Based on Blinded MRI Brain Data at Week 40ARIA is a Known Risk Factor for Anti-Amyloid Antibody DrugsMRI Data Presented at the 16th CTAD Conference in Boston, MA AUSTIN, Texas, Oct. 25, 2023 (GLOBE NEWSWIRE) -- Cassava Sc... Full story
Yahoo Finance • 7 months ago
ATLANTA, Oct. 17, 2023 (GLOBE NEWSWIRE) -- Holzer & Holzer, LLC is investigating whether Cassava Sciences, Inc. (“Cassava” or “the Company”) (NASDAQ: SAVA) complied with federal securities laws. On October 12, 2023, Science reported tha... Full story
Yahoo Finance • 7 months ago
CUNY’s report makes no findings of data manipulation.The “egregious misconduct” cited in the report relates to internal record-keeping failures at CUNY.CUNY’s report finds that internal record-keeping failures “prevented us [CUNY] from mak... Full story
Yahoo Finance • 7 months ago
AUSTIN, Texas, Oct. 05, 2023 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a biotechnology company committed to the treatment of Alzheimer’s disease dementia, today announced that Remi Barbier, President & Chief Executive Of... Full story
Yahoo Finance • 8 months ago
804 Alzheimer’s Patients Are Enrolled in a Pivotal Phase 3 Clinical TrialA Second Pivotal Phase 3 Clinical Trial Is Expected to Complete Enrollment Q4 2023, With a Target Enrollment of Approximately 1,100 Patients. AUSTIN, Texas, Oct. 02... Full story
Yahoo Finance • 8 months ago
An Independent Data and Safety Monitoring Board (DSMB) Recently Evaluated the Interim Patient Safety Database for Simufilam in On-Going Phase 3 Clinical Trials. The DSMB Recommended the Phase 3 Trials of Simufilam Continue as Planned, With... Full story
Yahoo Finance • 8 months ago
New cell biology data from Europe shows simufilam interrupts a pathogenic signaling pathway in Alzheimer’s disease.Results corroborate prior research from other academic researchers.These data once again confirm the biological activity of... Full story
Yahoo Finance • 8 months ago
AUSTIN, Texas, Sept. 06, 2023 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a biotechnology company committed to the treatment of Alzheimer’s disease dementia, today announced that it has been invited to present at the follo... Full story
Yahoo Finance • 10 months ago
Simufilam Slowed Cognitive Decline by 38% Versus Placebo Over 6 months in Patients with Mild-to-Moderate Alzheimer’s Disease.Drug Effects Favored Mild Alzheimer’s Disease.In Mild Alzheimer’s, Simufilam Improved Cognition Scores Over 6 Mont... Full story
Yahoo Finance • a year ago
Overactive mTOR Plays a Key Role in Aging and Alzheimer’s Disease. Simufilam Suppresses Overactive mTOR, Suggesting a Beneficial Drug Effect. Research is Published in Frontiers in Aging, a Peer-reviewed Journal. AUSTIN, Texas, June 27, 2... Full story
Yahoo Finance • a year ago
Publication Reviews Certain Receptor-Protein Interactions. Provides Overview of Basic Science Supporting Simufilam. Published in Drug Development Research, a Peer-Reviewed Journal. AUSTIN, Texas, June 12, 2023 (GLOBE NEWSWIRE) -- Cass... Full story
Yahoo Finance • a year ago
The Cognition Maintenance Study (CMS) is a 6-month, Randomized Controlled Trial of Simufilam in Over 125 Patients with Alzheimer’s Disease. Primary Outcome Measures Are Safety and Change in Cognition Scores. Top-line Clinical Results of th... Full story
Yahoo Finance • a year ago
Over 1,244 Alzheimer’s patients now enrolled in Phase 3 studies of simufilam.Completion of patient enrollment for Phase 3 program still expected Q4 2023.$187.5 Million Cash and Cash Equivalents at March 31, 2023. AUSTIN, Texas, May 01, 2... Full story
Yahoo Finance • a year ago
AUSTIN, Texas, April 26, 2023 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company focused on Alzheimer’s disease, today announced that Remi Barbier, President & Chief Executive Officer, has b... Full story
Home
Money Search
Trending Sports
Gallery
Shop
Blog
Examples
Data & Glossary
Elements of Bball
Harden Maze
About
